AB&B BIO-TECH-B

Jiangsu Zhonghui Yuantong Technology Co., Ltd. has a registered capital of 0.36 billion yuan and is committed to the R&D, manufacture and commercialization of innovative vaccines and traditional vaccines using new technological methods. A number of viral vaccines, bacterial vaccines, conjugate vaccines, subunit vaccines and mRNA vaccine pipelines are being promoted simultaneously at the Shanghai/Taizhou R&D center and pilot platform. Currently, the company's quadrivalent influenza virus subunit vaccine (3 years and above) has been marketed for sale. The NDA application for quadrivalent influenza virus subunit vaccine (age 6-35 months) has been accepted. The 23-valent pneumococcal polysaccharide vaccine and freeze-dried human rabies vaccine (human diploid cells) have completed phase I clinical trials. A number of academic results have been published in the authoritative international journal Vaccine, and have been continuously quoted in the “Technical Guidelines for Chinese Influenza Vaccine Vaccination” in recent years. The company's No. 1 production park is equipped with supporting facilities such as production workshops, central laboratories, and warehousing centers that meet the requirements of national standards. The construction of the world-class influenza stock solution workshop and formulation workshop GMP production line has been completed, and the vaccine “Production License” and “Laboratory Animal Use License” have been obtained; the No. 2/No. 3 production park is under intense construction. It has won honorary titles such as “2024 Jiangsu Specialized and New Small and Medium Enterprises”, “2022 Jiangsu High-tech Industrial Development Zone Potential Unicorn Enterprise”, “Jiangsu High-tech Zone Gazelle Enterprise”, and “Taizhou Top Ten Industrial Transformation and Innovation Investment Projects”. Currently, the core team members are all professionals in the field of Biologics production and research and development from home and abroad, and have many years of experience in vaccine research and development, production, testing and management. The company received 1 national talent project support, and Taizhou's “113 Talents” high-level innovation and entrepreneurship talent program supports many projects. It is Zhonghui Biotech's founding principle to not simply replicate it, target international trends, and make innovative vaccines. Caring for life and protecting health is Zhonghui Biotech's mission! Zhonghui Biotech will carry forward the spirit of innovation, pragmatism, self-discipline, honesty, and constant perseverance, and make unremitting efforts so that China can use innovative vaccines from around the world and the world can use China's high-quality vaccines!